Bristol-Myers Stops Skin Cancer Study on Positive Data

June 25, 2014 12:55 AM

5 0

Bristol-Myers Squibb Co. (BMY) said it stopped a late-stage study of a top experimental drug after skin cancer patients showed “superior overall survival” with the medicine compared with a group on chemotherapy alone.

Patients in the chemotherapy group were “unblinded” and allowed to take the experimental drug, called nivolumab, after an analysis by the trial’s independent data monitoring committee, Bristol-Myers said today in a statement.

Read more

To category page